Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Accounts Payables (2020 - 2025)

Foghorn Therapeutics has reported Accounts Payables over the past 6 years, most recently at $11.4 million for Q4 2025.

  • Quarterly results put Accounts Payables at $11.4 million for Q4 2025, up 200.05% from a year ago — trailing twelve months through Dec 2025 was $11.4 million (up 200.05% YoY), and the annual figure for FY2025 was $11.4 million, up 200.05%.
  • Accounts Payables for Q4 2025 was $11.4 million at Foghorn Therapeutics, up from $3.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for FHTX hit a ceiling of $11.4 million in Q4 2025 and a floor of $2.9 million in Q1 2021.
  • Median Accounts Payables over the past 5 years was $5.5 million (2022), compared with a mean of $5.7 million.
  • Biggest five-year swings in Accounts Payables: crashed 58.31% in 2021 and later skyrocketed 200.05% in 2025.
  • Foghorn Therapeutics' Accounts Payables stood at $3.8 million in 2021, then surged by 41.76% to $5.4 million in 2022, then increased by 15.63% to $6.3 million in 2023, then crashed by 39.54% to $3.8 million in 2024, then skyrocketed by 200.05% to $11.4 million in 2025.
  • The last three reported values for Accounts Payables were $11.4 million (Q4 2025), $3.2 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.